U.S. Light Therapy Market Size, Share, and Growth Forecast, 2025 - 2032

U.S. Light Therapy Market Size and Trends Analysis

The U.S. light therapy market size is likely to be valued at US$353.3 Mn in 2025. It is expected to reach US$493.9 Mn by 2032, growing at a CAGR of 4.9% during the forecast period from 2025 to 2032, driven by rising awareness of mental health and sleep hygiene, increasing prevalence of lifestyle-related sleep disturbances, and a growing emphasis on non-pharmacological approaches to chronic conditions.

Key Industry Highlights:

• Fastest-Growing Product Type: Handheld devices are expanding rapidly, due to portability, affordability, and strong adoption in home-based therapy for skin, mood, and sleep-related conditions.
• Leading Application Type: Skin conditions are likely to account for over 34.7% of the market share of the U.S. light therapy market in 2025, driven by the high prevalence of acne, psoriasis, eczema, and vitiligo, along with growing clinical acceptance of light therapy as a safe, non-invasive treatment option.
• Dominant End-user: Home healthcare is projected to account for about 61.1% of the U.S. light therapy market in 2025, driven by convenience, rising self-care trends, and growing use of light therapy for everyday wellness.
• Emerging Opportunity: Wearable light visors and app-integrated solutions are gaining attention, driven by consumer demand for enhanced mobility, real-time therapy tracking, and seamless integration with digital health ecosystems.

Key Insights	Details
U.S. Light Therapy Market Size (2025E)	US$353.3 Mn
Market Value Forecast (2032F)	US$493.9 Mn
Projected Growth (CAGR 2025 to 2032)	4.9%
Historical Market Growth (CAGR 2019 to 2024)	4.1%

Market Factors - Growth, Barriers, and Opportunity Analysis

Seasonal Affective Disorder (SAD) & Mental Health Awareness

Seasonal Affective Disorder (SAD) and growing mental health awareness are key drivers of the U.S. light therapy market. Approximately 5% of U.S. adults experience full SAD annually, while another 10-15% report milder seasonal mood disruptions.

Beyond seasonal depression, about 13% of adolescents and adults experience depressive symptoms within any two weeks, highlighting a significant population that benefits from non-drug interventions.

Sleep disturbances, often linked to mood disorders, affect 14-15% of adults who have difficulty falling asleep and 17-18% who struggle to stay asleep. In contrast, nearly one-third of adults regularly get insufficient sleep.

These high prevalence rates, combined with public interest in safe, non-invasive treatments, are driving the adoption of light therapy solutions as effective tools for mood regulation and sleep improvement across the U.S. population. Growing awareness of mental health and wellness continues to reinforce the market’s long-term growth potential.

Lack of Standardized Treatment Protocols

The lack of standardized treatment protocols in light therapy is a significant restraint in the U.S. market, particularly impacting the adoption and clinical acceptance of these therapies. For instance, while the World Association for Laser Therapy (WALT) has proposed dosage guidelines for various conditions, these recommendations vary widely.

For example, treatment durations range from 30 seconds to 10 minutes for 904-nm lasers, and from 20 seconds to 5 minutes for lasers in the 780-860 nm range, with energy levels varying from 5 to 500 mW. Such variability complicates the development of consistent treatment protocols.

Furthermore, the U.S. Food and Drug Administration (FDA) emphasized the need for clear clinical evidence to support at-home phototherapy claims, particularly for conditions such as acne and psoriasis. This regulatory scrutiny necessitates more rigorous clinical trials, which could delay product availability and increase costs, thereby affecting market growth.

Therefore, the absence of standardized treatment protocols and the need for robust clinical validation are pivotal challenges hindering the expansion of the light therapy market in the U.S.

Rising Prevalence of Skin Disorders

The rising prevalence of skin disorders in the U.S. presents a significant opportunity for the expansion of light therapy treatments. According to the National Center for Complementary and Integrative Health, skin diseases affect as many as one in three Americans at any given time.

Conditions such as acne, psoriasis, and eczema are commonly treated with light therapy, including UVB phototherapy and intense pulsed light (IPL) systems, which have been FDA-cleared for these indications.

The lack of standardized treatment protocols remains a challenge. Variability in light wavelength, exposure time, and treatment parameters can lead to inconsistent outcomes. For instance, the MultiClearXL system is indicated for both UVB and visible blue/violet light treatments for conditions such as psoriasis and acne vulgaris.

Such variations underscore the need for standardized guidelines to ensure efficacy and safety. Addressing this gap through research and consensus could enhance the clinical adoption and effectiveness of light therapy in treating prevalent skin disorders.

Category-wise Analysis

Product Type

Handheld devices lead the U.S. light therapy market with a 27.6% share in 2025, due to their convenience, affordability, and versatility. Unlike large clinical units, these devices allow consumers to administer treatments at home, saving time and reducing dependency on professional clinics.

They are particularly popular among younger, tech-savvy users seeking non-invasive solutions for skin conditions such as acne, wrinkles, and hyperpigmentation, as well as for wellness purposes such as pain relief and mood enhancement.

The FDA has cleared several at-home handheld devices, boosting consumer confidence in their safety and efficacy. Moreover, their compact size and multi-mode functionality, offering red, blue, and infrared light in a single device, make them versatile for multiple applications. Increasing awareness of self-care and non-pharmaceutical interventions further drives their market dominance in the U.S. light therapy sector.

Application Insights

Skin conditions lead the U.S. light therapy market with a 34.7% share in 2025, as they represent the most common and visible health concerns that can be effectively managed with phototherapy. Conditions such as acne, psoriasis, eczema, and fine lines affect millions of Americans, creating consistent demand for safe and non-invasive treatments.

Light therapy, including blue, red, and near-infrared wavelengths, has been clinically validated to reduce inflammation, kill acne-causing bacteria, and promote collagen production, making it a preferred alternative to chemical-based treatments.

Additionally, FDA clearance of various devices for at-home use has made treatments more accessible, allowing users to address skin concerns conveniently. Rising consumer interest in aesthetics, anti-aging, and dermatological wellness, coupled with increasing awareness of the benefits of light therapy, further reinforces its dominance as the leading application segment in the U.S. market.

Competitive Landscape

The U.S. light therapy market is competitive, led by players such as Joovv, Verilux, and HoMedics. These companies focus on device innovation, multi-wavelength functionality, portability, and FDA-cleared home-use solutions, while emerging players emphasize affordability, niche applications, and user-friendly designs to cater to skin, mental health, and wellness segments, targeting both clinical and at-home consumers.

Key Industry Developments

• In August 2025, the founder of MITO Red Light Therapy stated that modern lifestyles, characterized by long hours spent indoors and limited sun exposure, have created a growing need for photon supplementation. He emphasized that insufficient natural sunlight has been linked to various health concerns, including disrupted circadian rhythms, fatigue, and reduced cellular function.
• In August 2025, Celluma Light Therapy celebrated a triple win at the 2025 Awards, earning recognition across multiple categories for its innovative light therapy solutions. The company was honored for excellence in product design, technological innovation, and its impact on patient outcomes.
• In August 2025, a pilot study demonstrated that daily bright light therapy (BLT) can significantly improve visual function in individuals with Parkinson’s disease (PD). The randomized, placebo-controlled trial involved 23 PD patients who received one month of either BLT or dim light therapy (DLT), with a one-month washout period between treatments.
• In November 2024, the U.S. Food and Drug Administration (FDA) approved the Valeda Light Delivery System, developed by LumiThera, as the first non-invasive treatment for vision loss associated with dry age-related macular degeneration (AMD). This approval marked a significant advancement in the management of dry AMD, a leading cause of vision impairment in individuals over 55.
• In March 2024, Celluma Light Therapy announced the launch of its revolutionary body contouring device, marking a significant expansion of its product portfolio. The new device was designed to combine advanced light therapy with non-invasive body shaping technology, offering users a safe and effective method to improve body aesthetics.

Companies Covered in U.S. Light Therapy Market

• Mito Red Light
• Verilux
• Infraredi
• Celluma
• Omnilux
• Joovv
• TheraLight
• Zerigo Health
• HigherDOSE
• Nanoleaf
• Northern Light Technologies
• Naturebright